Shamburg News · 8-K filed Nov 12, 2026, 4:40 PM EST
DiaMedica Therapeutics Reports Third Quarter 2026 Financial Results and Business Update
DMAC · DiaMedica Therapeutics Inc.
- Earnings
- Materiality: high
On November 12, 2026, DiaMedica Therapeutics Inc. reported unaudited financial results for the quarter ended September 30, 2026, with a net loss of $11.3 million, or $0.21 per basic and diluted share. Research and development expenses were $9.2 million for the quarter, and cash, cash equivalents and short-term investments totaled $34.9 million at quarter end. The company also provided a business update on its DM199 clinical programs, including completed enrollment in the first two cohorts of its Phase 2 early-onset fetal growth restriction trial.
Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001437749-26-036600.
Written from the filing by Shamburg Markets. Figures are as reported by the company.